NASDAQ:ADAPAdaptimmune Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC - Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.07 +0.09 (+1.13 %) (As of 08/10/2020 11:10 AM ET) Add Compare Share Today's Range$7.96Now: $8.07▼$8.1350-Day Range$8.06MA: $9.28▼$10.1652-Week Range$0.71Now: $8.07▼$13.40Volume2,349 shsAverage Volume894,746 shsMarket Capitalization$1.05 billionP/E RatioN/ADividend YieldN/ABeta2.34 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Adaptimmune Therapeutics has a potential upside of ∞ from its current price of $0.00.Amount of Analyst CoverageAdaptimmune Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesAdaptimmune Therapeutics has received 290 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdaptimmune Therapeutics has received 296 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdaptimmune Therapeutics has received 50.51% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Adaptimmune Therapeutics and other stocks. Vote “Outperform” if you believe ADAP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADAP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have sold 5,983.43% more of their company's stock than they have bought. Specifically, they have bought $77,841.00 in company stock and sold $4,735,402.00 in company stock.Percentage Held by InsidersOnly 18.89% of the stock of Adaptimmune Therapeutics is held by insiders.Percentage Held by Institutions72.13% of the stock of Adaptimmune Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.97) to ($1.06) per share. Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADAP Previous Symbol CUSIPN/A CIK1621227 Webwww.adaptimmune.com Phone44-12-3543-0000Debt Debt-to-Equity RatioN/A Current Ratio11.88 Quick Ratio11.88Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.12 million Price / Sales937.49 Cash FlowN/A Price / Cash FlowN/A Book Value$1.18 per share Price / Book6.84Profitability EPS (Most Recent Fiscal Year)($1.32) Net Income$-137,160,000.00 Net Margins-5,687.30% Return on Equity-58.60% Return on Assets-42.69%Miscellaneous Employees406 Outstanding Shares130,110,000Market Cap$1.05 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $8.07 +0.09 (+1.13 %) (As of 08/10/2020 11:10 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ADAP News and Ratings via Email Sign-up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Adaptimmune Therapeutics (NASDAQ:ADAP) Frequently Asked Questions How has Adaptimmune Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Adaptimmune Therapeutics' stock was trading at $2.94 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ADAP shares have increased by 174.5% and is now trading at $8.07. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Adaptimmune Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptimmune Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Adaptimmune Therapeutics. When is Adaptimmune Therapeutics' next earnings date? Adaptimmune Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Adaptimmune Therapeutics. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics PLC - (NASDAQ:ADAP) posted its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.24). Adaptimmune Therapeutics had a negative net margin of 5,687.30% and a negative return on equity of 58.60%. View Adaptimmune Therapeutics' earnings history. What price target have analysts set for ADAP? 4 analysts have issued 1 year price objectives for Adaptimmune Therapeutics' shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Adaptimmune Therapeutics' stock price to reach $8.00 in the next twelve months. This suggests that the stock has a possible downside of 0.9%. View analysts' price targets for Adaptimmune Therapeutics. Has Adaptimmune Therapeutics been receiving favorable news coverage? News articles about ADAP stock have trended very positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adaptimmune Therapeutics earned a coverage optimism score of 3.2 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Adaptimmune Therapeutics. Who are some of Adaptimmune Therapeutics' key competitors? Some companies that are related to Adaptimmune Therapeutics include China Biologic Products (CBPO), Sorrento Therapeutics (SRNE), Halozyme Therapeutics (HALO), Ablynx (ABLYF), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Twist Bioscience (TWST), Immunovant (IMVT), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Mesoblast (MESO), Legend Biotech (PCVX), Sangamo Therapeutics (SGMO) and BAVARIAN NORDIC/S (BVNRY). View all competitors. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CA (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), BlackRock (BLK), Shopify (SHOP), Cara Therapeutics (CARA), Micron Technology (MU) and Chipotle Mexican Grill (CMG). Who are Adaptimmune Therapeutics' key executives? Adaptimmune Therapeutics' management team includes the following people: Mr. James Julian Noble, CEO & Director (Age 60)Dr. Helen Katrina Tayton-Martin, Co-Founder & Chief Bus. Officer (Age 52)Mr. Adrian Rawcliffe, Chief Financial Officer (Age 47)Mr. William C. Bertrand Jr., Chief Operating Officer (Age 54)Dr. Rafael Amado, Pres of R&D (Age 55) When did Adaptimmune Therapeutics IPO? (ADAP) raised $150 million in an IPO on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners served as the underwriters for the IPO and Guggenheim Securities was co-manager. What is Adaptimmune Therapeutics' stock symbol? Adaptimmune Therapeutics trades on the NASDAQ under the ticker symbol "ADAP." Who are Adaptimmune Therapeutics' major shareholders? Adaptimmune Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (1.47%), Rathbone Brothers plc (0.34%), Alps Advisors Inc. (0.16%), Vident Investment Advisory LLC (0.11%), Vident Investment Advisory LLC (0.11%) and Leap Investments LP (0.03%). Company insiders that own Adaptimmune Therapeutics stock include Adrian Rawcliffe, Ali Behbahani, Elliot Norry, Enterprise Associates 14 New, Gavin Wood, Gwendolyn Knowlt Binder-Scholl, James Noble, John Lunger, Lawrence M Alleva, Peter W Sonsini, Rafael Amado and William C Bertrand, Jr. View institutional ownership trends for Adaptimmune Therapeutics. Which institutional investors are buying Adaptimmune Therapeutics stock? ADAP stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Alps Advisors Inc., Vident Investment Advisory LLC, Vident Investment Advisory LLC, Rathbone Brothers plc, Leap Investments LP, Virtus ETF Advisers LLC, and K.J. Harrison & Partners Inc. Company insiders that have bought Adaptimmune Therapeutics stock in the last two years include Ali Behbahani, Enterprise Associates 14 New, Gavin Wood, Lawrence M Alleva, and Peter W Sonsini. View insider buying and selling activity for Adaptimmune Therapeutics. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Adaptimmune Therapeutics' stock price today? One share of ADAP stock can currently be purchased for approximately $8.07. How big of a company is Adaptimmune Therapeutics? Adaptimmune Therapeutics has a market capitalization of $1.05 billion and generates $1.12 million in revenue each year. The biotechnology company earns $-137,160,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. Adaptimmune Therapeutics employs 406 workers across the globe. What is Adaptimmune Therapeutics' official website? The official website for Adaptimmune Therapeutics is www.adaptimmune.com. How can I contact Adaptimmune Therapeutics? Adaptimmune Therapeutics' mailing address is 60 JUBILEE AVENUE MILTON PARK OXFORDSHIRE, ABINGDON X0, OX14 4RX. The biotechnology company can be reached via phone at 44-12-3543-0000 or via email at [email protected] This page was last updated on 8/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
